11.17  1.12 (11.14%)		06-25 16:00
Open: 10.05 High: 11.22 Volume: 1,053,835		Pre. Close: 10.05 Low: 10.01 Market Cap: 1,009(M)

Short term
Mid term
Targets	6-month :	13.57	1-year :	15.85
Resists	First :	11.61	Second :	13.57
Pivot price	9.75
Supports	First :	9.84	Second :	8.75
MAs	MA(5) :	10.16	MA(20) :	9.82
	MA(100) :	8.24	MA(250) :	5.8
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	61.6	D(3) :	50.6
RSI	RSI(14): 63.1
52-week	High :	11.61	Low :	2.86

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ DRTS ] has closed Bollinger Bands are 5.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	11.23 - 11.28	11.28 - 11.31
Low:	9.91 - 9.96	9.96 - 9.99
Close:	11.09 - 11.17	11.17 - 11.24

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Thu, 25 Jun 2026
Alpha Tau Medical (NASDAQ: DRTS) shareholders back board, pay and auditor at AGM - Stock Titan

Thu, 25 Jun 2026
Insider Sell Alert: Raphi Levy Sells Shares of Alpha Tau Medical Ltd (DRTS) - GuruFocus

Thu, 25 Jun 2026
Oramed’s portfolio swells: Alpha Tau stake up $128M, Scilex loan repaid - Stock Titan

Thu, 25 Jun 2026
Alpha Tau Medical (DRTS) CFO reports open-market sale of 17,500 shares - Stock Titan

Tue, 23 Jun 2026
Alpha Tau Medical (Nasdaq: DRTS) treats first recurrent glioblastoma patient outside U.S. - Stock Titan

Tue, 23 Jun 2026
Alpha Tau first treats glioblastoma patient outside the U.S. in Israel - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Equipment & Services
Shares Out	90 (M)
Shares Float	62 (M)
Held by Insiders	31.2 (%)
Held by Institutions	4.6 (%)
Shares Short	1,790 (K)
Shares Short P.Month	1,020 (K)

EPS	-0.68
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.76
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-30.5 %
Return on Equity (ttm)	-90.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.5
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-16.68
PEG Ratio	0
Price to Book value	14.5
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.